首页> 外文期刊>International Journal of Pharmaceutics >Influence of end groups on in vitro release and biological activity of lysozyme from a phase-sensitive smart polymer-based in situ gel forming controlled release drug delivery system.
【24h】

Influence of end groups on in vitro release and biological activity of lysozyme from a phase-sensitive smart polymer-based in situ gel forming controlled release drug delivery system.

机译:端基对基于相敏智能聚合物的原位凝胶形成控释药物递送系统的溶菌酶的体外释放和生物学活性的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Phase-sensitive in situ gel forming controlled release formulations of lysozyme were prepared using poly lactic acid (PLA) and/or poly glycolic acid (PGA) based polymers differing in end groups in addition to composition, and a solvent system consisting of various ratios of benzyl benzoate (BB) and benzyl alcohol (BA). The amount of lysozyme in the released samples was determined by measuring absorbance at 280nm using suitable controls to nullify the effect of absorption of formulation degradation products. Biological activity of lysozyme was studied by an enzyme activity assay using Micrococcus lysodeikticus as substrate. Polymers bearing carboxylic acid end group were not soluble in 100% BB but polymers having ester end groups were soluble up to 27% (w/v) except polymer 4. A biphasic release profile consisting of slower first phase followed by faster second phase was observed. Formulations prepared from polymer with carboxylic acid groups showed significantly (p<0.05) lower burst release (4%) than those containing ester end groups (20-30%). However, formulations consisting of polymer with carboxylic acid end groups showed significantly (p<0.05) faster release rate of incorporated lysozyme, although the total amount released was less in comparison to the total amount released from formulations prepared using polymers containing ester end groups. The mean percentage specific enzyme activity (MPSEA) data were supported by the release profiles. In conclusion, polymer end groups may influence the release profiles of a protein from an in situ gel depot forming controlled release formulations.
机译:使用除了端基以外还具有不同端基的聚乳酸(PLA)和/或聚乙醇酸(PGA)基的聚合物以及由不同比例的溶剂组成的溶剂体系制备溶菌酶的相敏原位凝胶形成控释制剂。苯甲酸苄酯(BB)和苯甲醇(BA)。通过使用合适的对照物来消除制剂降解产物的吸收效应,通过测量280nm处的吸光度来确定释放的样品中的溶菌酶的量。以溶酶微球菌为底物,通过酶活性试验研究了溶菌酶的生物活性。带有羧酸端基的聚合物不溶于100%BB,但具有酯端基的聚合物可溶解至27%(w / v),而聚合物4除外。观察到由较慢的第一相和随后的较快的第二相组成的双相释放曲线。由具有羧酸基团的聚合物制备的制剂显示出比含有酯端基的制剂(20-30%)显着(p <0.05)更低的突释(4%)。然而,尽管与使用含酯端基的聚合物制备的制剂的释放总量相比,由具有羧酸端基的聚合物组成的制剂的掺入溶菌酶的释放速率显着更快(p <0.05),但是释放的总量却更少。释放曲线支持平均百分比酶活性(MPSEA)数据。总之,聚合物端基可能会影响蛋白质从原位凝胶长效制剂形成控释制剂的释放曲线。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号